Home > Insider Trading > Filing (0001209191-18-052368)

Filing Details

Accession Number:: 0001209191-18-052368
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-09-26 19:00:17
Reporting Period:: 2018-09-24

Accepted Time:: 2018-09-26 19:00:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1628738	Audentes Therapeutics Inc.	BOLD	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1238401	G Louis Lange	C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-09-24	19,800	$37.35	365,999	No	4	S	Direct
Common Stock	Disposition	2018-09-24	200	$37.76	365,799	No	4	S	Direct
Common Stock	Disposition	2018-09-24	1,000	$37.25	7,555	No	4	S	Indirect	By Adrienne M. MacMillan Revocable Trust
Common Stock	Disposition	2018-09-24	1,000	$37.27	18,678	No	4	S	Indirect	By Amygdala Lange Trust
Common Stock	Disposition	2018-09-24	1,000	$37.27	1,558	No	4	S	Indirect	By Lange Minor's Trust
Common Stock	Disposition	2018-09-24	10,000	$37.45	42,343	No	4	S	Indirect	By Asset Management Ventures Fund, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	By Adrienne M. MacMillan Revocable Trust
No	4	S	Indirect	By Amygdala Lange Trust
No	4	S	Indirect	By Lange Minor's Trust
No	4	S	Indirect	By Asset Management Ventures Fund, L.P.

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.72 and the highest price at which shares were sold was $37.71. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6) and (9) to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $37.75 and the highest price at which shares were sold was $37.76.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.84 and the highest price at which shares were sold was $37.61.
The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Represents the weighted average sale price. The lowest price at which shares were sold was $36.93 and the highest price at which shares were sold was $37.62.
The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
The reporting person's spouse is the trustee of the Lange Minor's Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Represents the weighted average sale price. The lowest price at which shares were sold was $37.00 and the highest price at which shares were sold was $37.675.
The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.